Portfolio Revenue Leakage Scan — June 2026

$6.4M
est. annual surgical revenue leakage
ENT & Allergy Associates portfolio

Across 1 portfolio companies · 40 surgical locations · 0.85 recovery confidence factor applied

Book a 20-min portfolio review Share with deal team
Methodology: Practice count × 2 ORs × 240 slots/yr × specialty cancel rate × avg slot value × 0.85 confidence | Benchmarks: ASCA 2023 + CMS 2024 reimbursement data

Per-Portfolio Company Breakdown

Sorted by estimated recoverable revenue — largest leakage first.

Portfolio Company Specialty Locations Est. Annual Cancellations Est. Recoverable Revenue Resources
ENT & Allergy Associates
 ENT/otolaryngology 40 1,978 slots/yr $6.4M
Memo · Board Pack
Portfolio Total 1 companies 40 — $6.4M / yr

*Estimated annual recoverable revenue using 0.85 confidence factor. Actual recovery depends on specialty mix, case volume, and CaseFlow fill-rate performance. Based on ASCA 2023 national benchmarks.

Top 3 Board Memos — Preview

One-page forwardable memos for the three highest-leakage portfolio companies. Ready for your IC deck or deal-team email.

Board Memo #1
ENT & Allergy Associates
ENT/otolaryngology · 40 locations
Est. Annual Recovery
$6.4M
Cancel rate10%
Avg slot value$3,800
Annual cancelled slots1,978
View Full Memo ⬇ Board Pack PDF
Get this report in your inbox

Forward to your deal team in one click.

Drop your email and we'll send you a clean, board-ready PDF of this entire portfolio scan — formatted for IC presentations.

No spam. Unsubscribe anytime. CAN-SPAM compliant.

Ready to recover this revenue?

20-minute portfolio review. We'll show you which portfolio companies to pilot first and what Day-14 results look like.

Book a 20-min portfolio review